Prometheus Biosciences shares soar after news that Merck is buying the company for about $10.8 billion.
Stock gainers:Stock decliners:. Here are some of the biggest movers on Monday:.
Stock gainers:Stock decliners:... Here are some of the biggest movers on Monday:Österreich Neuesten Nachrichten, Österreich Schlagzeilen
Similar News:Sie können auch ähnliche Nachrichten wie diese lesen, die wir aus anderen Nachrichtenquellen gesammelt haben.
Merck in late-stage talks to acquire Prometheus Biosciences -WSJMerck & Co is in late-stage talks to acquire Prometheus Biosciences Inc to get its hands on promising immune disease treatments, the Wall Street Journal reported on Sunday citing people familiar with the matter.
Weiterlesen »
Merck to buy Prometheus Biosciences for about $11 blnMerck & Co has agreed to acquire Prometheus Biosciences Inc for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Weiterlesen »
Merck in talks to acquire Prometheus Biosciences: reportMerck is reportedly in talks to buy the San Diego-based Prometheus Biosciences in a promising deal that could be announced as early as Sunday.
Weiterlesen »
Merck to buy Prometheus Biosciences for about $11 billionMerck has agreed to acquire Prometheus Biosciences for about $10.8 billion to bolster the company's presence in immunology, the companies said on Sunday.
Weiterlesen »
Merck to acquire Prometheus Biosciences for $10.8BMerck is acquiring San Diego-based Prometheus Biosciences in a $10.8 billion deal.
Weiterlesen »
Merck to buy Prometheus Biosciences for $10.8 billionMerck & Co. Inc. announced Sunday a deal to acquire Prometheus Biosciences Inc. for $200 a share, or about $10.8 billion.
Weiterlesen »